

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

Application Number	10/553,703
Filing Date	April 16, 2004
First Named Inventor	FIKES, John D.
Art Unit	1642
Examiner Name	DAVIS, Minh Tam B.
Attorney Docket Number	2060.0150007/EKS/PAC

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	FP1	WO 94/020127 A1	09/15/1994	Cytel Corporation		
	FP2	WO 95/04817 A1	02/16/1995	Cytel Corporation		
	FP3	WO 95/22561 A2	08/24/1995	University of Virginia Patent Foundation		
	FP4	WO 96/18409 A1	06/20/1996	The Scripps Research Institute		
	FP5	WO 98/33888 A1	08/06/1998	Epimmune, Inc.		
	FP6	WO 01/41741 A1	06/14/2001	Epimmune, Inc.		
	FP7	WO 02/10379 A2	02/07/2002	Aventis Pasteur Limited; Therion Biologics; National Cancer Institute		

981524v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,703
				Filing Date	April 16, 2004
				First Named Inventor	FIKES, John D.
				Art Unit	1642
				Examiner Name	DAVIS, Minh Tam B.
Sheet	1	of	3	Attorney Docket Number	2060.0150007/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Alters, S.E., <i>et al.</i> , "Immunotherapy of Cancer: Generation of CEA Specific CTL Using CEA Peptide Pulsed Dendritic Cells," <i>Dendritic Cells in Fund. and Clin. Immunol.</i> 3:519-524, Plenum Press, United States (1997)	
	NPL2	Bakker, A.B.H., <i>et al.</i> , "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope," <i>Int. J. Cancer</i> 70:302-309, Wiley-Liss, United States (1997)	
	NPL3	Bremers, A.J.A., <i>et al.</i> , "The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related HLA-A*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes," <i>J. Immunother.</i> 18:77-85, Lippincott-Raven, United States (1995)	
	NPL4	Celis, E., <i>et al.</i> , "Epitope selection and development of peptide based vaccines to treat cancer," <i>Semin. Cancer Biol.</i> 6:329-336, Academic Press, England (1995)	
	NPL5	Chikamatsu, K., <i>et al.</i> , "Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells," <i>Clin. Cancer Res.</i> 5:1281-1288, the American Association for Cancer Research, United States (1999)	
	NPL6	Cox, A.L., <i>et al.</i> , "Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines," <i>Science</i> 264:716-719, American Association for the Advancement of Science, United States (1994)	
	NPL7	DeLeo, A.B. "p53-Based Immunotherapy of Cancer," <i>Crit. Rev. Immunol.</i> 18:29-35, Begell House, Inc., United States (1998)	
	NPL8	Gambacorti-Passerini, C., <i>et al.</i> , "Mapping of HLA Class I Binding Motifs in Forty-four Fusion Proteins Involved in Human Cancers," <i>Clin. Cancer Res.</i> 3:675-683, The Association, United States (1997)	
	NPL9	Greenberg, P.D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," <i>Adv. Immunol.</i> 49:281-355, Academic Press, United States (1991)	
	NPL10	Ioannides, C.G., <i>et al.</i> , "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," <i>Mol. Carcinog.</i> 6:77-82, Wiley-Liss, United States (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,703
				Filing Date	April 16, 2004
				First Named Inventor	FIKES, John D.
				Art Unit	1642
				Examiner Name	DAVIS, Minh Tam B.
Sheet	2	of	3	Attorney Docket Number	2060.0150007/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL11	Kawashima, I., <i>et al.</i> , "Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/ <i>neu</i> by Primary <i>in Vitro</i> Immunization with Peptide-pulsed Dendritic Cells," <i>Cancer Res.</i> 59:431-435, American Association for Cancer Research, United States (1999)	
	NPL12	Keogh, E., <i>et al.</i> , "Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity," <i>J. Immunol.</i> 167:787-796, American Association of Immunologists, United States (2001)	
	NPL13	Lustgarten, J., <i>et al.</i> , "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A2.1 and Human CD.8," <i>Hum. Immunol.</i> 52:109-118, Elsevier Science, United States (1997)	
	NPL14	Mateo, L., <i>et al.</i> , "An HLA-A2 Polyepitope Vaccine for Melanoma Immunotherapy," <i>J. Immunol.</i> 163:4058-4063, American Association of Immunologists, United States (1999)	
	NPL15	Melief, C.J.M., and Kast, W.M., "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General," <i>Cancer Surv.</i> 13:81-99, Cold Spring Harbor Press, United States (1992)	
	NPL16	Parkhurst, M.R., <i>et al.</i> , "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues," <i>J. Immunol.</i> 157:2539-2548, American Association of Immunologists, United States (1996)	
	NPL17	Petersen, T.R., <i>et al.</i> , "Identification and Design of p53-Derived HLA-A2-Binding Peptides with Increased CTL Immunogenicity," <i>Scand. J. Immunol.</i> 53:357-364, Blackwell Science Ltd., England (2001)	
	NPL18	Ras, E., <i>et al.</i> , "Identification of Potential HLA-A*0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA)," <i>Hum. Immunol.</i> 53:81-89, Elsevier Science, United States (1997)	
	NPL19	Rivoltini, L., <i>et al.</i> , "Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes. Implications for Peptide-Based Immunotherapy," <i>J. Immunol.</i> 156:3882-3891, American Association of Immunologists, United States (1996)	
	NPL20	Toes, R.E.M., <i>et al.</i> , "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," <i>Proc. Natl. Acad. Sci. USA</i> 94:14660-14665, National Academy of Sciences, United States (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,703
				Filing Date	April 16, 2004
				First Named Inventor	FIKES, John D.
				Art Unit	1642
				Examiner Name	DAVIS, Minh Tam B.
Sheet	3	of	3	Attorney Docket Number	2060.0150007/EKS/PAC

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL21	Tsang, K.Y., <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87:982-990, Oxford University Press, United States (1995)	
	NPL22	Valmori, D., <i>et al.</i> , "Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients," <i>Cancer Res.</i> 57:735-741, American Association for Cancer Research, United States (1997)	
	NPL23	International Search Report for International Application No. PCT/US04/11895, mailed June 27, 2008, ISA/US, United States	
	NPL24	Supplementary European Search Report for European Application No. 04 75 9962, mailed May 6, 2009, European Patent Office, Germany	
	NPL25	Examiner's First Report for Australian Application No. 2004232971, mailed December 16, 2008, Australian Patent Office, Australia	

981531v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.